{"product_id":"wolverine-blend","title":"Wolverine Blend","description":"\u003ch2\u003eAbout Wolverine Blend\u003c\/h2\u003e\n\u003cp\u003eWolverine Blend is a two component research preparation in which BPC-157 and TB-500 are co lyophilized together in a single sealed vial, giving 10 mg of total peptide content per vial. The two peptides are chemically unrelated and act through different reported mechanisms, so the preparation is best understood as two distinct research materials presented in one container rather than as a single defined chemical entity. Because it is a mixture, the blend has no single molecular formula, molecular weight or CAS number, and each component is specified separately below. Peptsche supplies Wolverine Blend strictly as a research material for controlled laboratory investigation.\u003c\/p\u003e\n\n\u003ch3\u003eAvailable Sizes\u003c\/h3\u003e\n\u003cp\u003eThis listing covers one vial configuration. Each component is assayed before blending, so the stated purity applies to the batch shipped.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e10mg vial of co lyophilized Wolverine Blend, comprising BPC-157 5 mg and TB-500 5 mg, each 99% or greater purity by HPLC\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eProduct Specifications\u003c\/h3\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWolverine Blend (BPC-157 and TB-500)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use only. Laboratory and in vitro investigation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAppearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWhite to off white lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eComposition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBPC-157 5 mg and TB-500 5 mg, co lyophilized in a single vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBPC-157 Component\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eChemical formula C\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e, molecular weight 1419.5 g\/mol, CAS 137525-51-0, PubChem CID \u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9941957\" target=\"_blank\" rel=\"noopener\"\u003e9941957\u003c\/a\u003e, sequence Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTB-500 Component\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eChemical formula C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e68\u003c\/sub\u003eN\u003csub\u003e10\u003c\/sub\u003eO\u003csub\u003e14\u003c\/sub\u003e, molecular weight 889.0 g\/mol, CAS 885340-08-9, PubChem CID \u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/62707662\" target=\"_blank\" rel=\"noopener\"\u003e62707662\u003c\/a\u003e, sequence Ac Leu Lys Lys Thr Glu Thr Gln OH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBPC-157 and TB-500 blend, recovery research blend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e99% or greater by HPLC, verified per batch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStore sealed at 2 to 8 °C, protected from heat, light and moisture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use blend. Neither component is approved for human or veterinary use in any jurisdiction. TB-500 appears on the United States Food and Drug Administration list of bulk drug substances withdrawn from consideration for compounding.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\n\u003ch2\u003eWhat is Wolverine Blend?\u003c\/h2\u003e\n\u003cp\u003eBPC-157 is a fifteen residue sequence derived from a fragment of a protein identified in gastric juice. It contains no unnatural residues and no chemical modification, and its stability in acidic conditions is one of the properties most often noted in the literature.\u003c\/p\u003e\n\u003cp\u003eTB-500 is a synthetic acetylated seven residue peptide corresponding to the actin binding region of the larger protein thymosin beta 4. It is not the full protein but the short active fragment, prepared with an N terminal acetyl group and a free acid C terminus.\u003c\/p\u003e\n\u003cp\u003eThe published record for both peptides is preclinical, comprising cell culture and animal model work, and importantly the two have been studied separately rather than in combination. No published study characterises this two component blend as such. Peptsche makes no claim that the preparation produces any outcome in a human or animal subject.\u003c\/p\u003e\n\n\u003ch2\u003eWolverine Blend Mechanism of Action (Research Only)\u003c\/h2\u003e\n\u003cp\u003eBecause this is a mixture, mechanism is described per component. The summaries below report preclinical observations and do not describe effects in humans.\u003c\/p\u003e\n\n\u003ch3\u003eNitric Oxide and Angiogenic Signalling from the BPC-157 Component\u003c\/h3\u003e\n\u003cp\u003eMechanistic reports for this component centre on vascular signalling. Seiwerth and colleagues reviewed observations relating the peptide to blood vessel behaviour in animal preparations, and Hsieh and colleagues described modulation of vasomotor tone through a signalling axis involving Src, caveolin 1 and endothelial nitric oxide synthase in the systems they examined.\u003c\/p\u003e\n\n\u003ch3\u003eActin Binding and Cytoskeletal Dynamics from the TB-500 Component\u003c\/h3\u003e\n\u003cp\u003eThe reported mechanism here is entirely different. The parent protein thymosin beta 4 sequesters monomeric actin, and the fragment retains the actin binding motif. Malinda and colleagues reported directional migration of cultured human umbilical vein endothelial cells, an endpoint that depends on cytoskeletal reorganisation rather than on receptor mediated vascular signalling.\u003c\/p\u003e\n\n\u003ch3\u003eTwo Mechanisms, Studied Separately\u003c\/h3\u003e\n\u003cp\u003eThe two components engage unrelated pathways, one vascular signalling and one cytoskeletal. That is the rationale investigators give for examining them together. It must be stated plainly that the published literature studies each peptide on its own. Whether combining them produces additive, independent or interfering behaviour is an open question that the existing evidence base does not answer.\u003c\/p\u003e\n\n\u003ch3\u003eIntegrated Mechanistic Profile\u003c\/h3\u003e\n\u003cp\u003eThe preclinical literature describes this preparation through three connected themes.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eVascular signalling.\u003c\/strong\u003e Reported nitric oxide and angiogenic observations attributed to the BPC-157 component.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCytoskeletal dynamics.\u003c\/strong\u003e Actin binding and cell migration endpoints attributed to the TB-500 component.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCombination untested.\u003c\/strong\u003e Published work examines the components separately, not as a blend.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e Wolverine Blend is supplied strictly for research use only. It is intended as an experimental compound for qualified laboratory personnel and is not a drug, food or cosmetic.\u003c\/p\u003e\n\u003cp\u003eWolverine Blend is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Applications (Observations from Studies)\u003c\/h2\u003e\n\u003cp\u003eThe areas below describe reported research uses of the individual components.\u003c\/p\u003e\n\n\u003ch3\u003eEndothelial and Vascular Cell Culture\u003c\/h3\u003e\n\u003cp\u003eCultured endothelial cells are the common system for both peptides. Reported endpoints include migration across a defined gap, tube formation on matrix substrate and markers of nitric oxide synthase activity in those specific preparations.\u003c\/p\u003e\n\n\u003ch3\u003eAnimal Model Tissue Studies\u003c\/h3\u003e\n\u003cp\u003eRodent models appear throughout the literature for both components, with investigators reporting differences in tissue composition between treated and untreated groups. Those reports are specific to the species, model design and conditions of each paper and do not transfer to other settings.\u003c\/p\u003e\n\n\u003ch3\u003eCytoskeletal and Analytical Reference Use\u003c\/h3\u003e\n\u003cp\u003eThe TB-500 fragment also serves as a reference ligand in actin polymerisation assays. Both peptides are used by method development groups establishing chromatographic retention and mass spectrometric fragmentation behaviour for short synthetic sequences.\u003c\/p\u003e\n\n\u003cp\u003eWolverine Blend is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eWolverine Blend Compared With Related Research Compounds\u003c\/h2\u003e\n\u003cp\u003eThe table below places Wolverine Blend alongside two related compounds in the Peptsche range. It is offered to clarify differences in classification, molecular target and research context. It should not be read as a comparison of clinical performance, safety, or suitability for any application.\u003c\/p\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCharacteristic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWolverine Blend\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResearch Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwo component co lyophilized research blend\u003c\/td\u003e\n\u003ctd\u003eSynthetic pentadecapeptide\u003c\/td\u003e\n\u003ctd\u003eSynthetic acetylated seven residue peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Molecular Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNitric oxide signaling and monomeric G actin, addressed by separate components\u003c\/td\u003e\n\u003ctd\u003eNitric oxide and angiogenic signaling pathways\u003c\/td\u003e\n\u003ctd\u003eMonomeric G actin within the cytoskeleton\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanistic Profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwo unrelated pathways, combination not studied in published work\u003c\/td\u003e\n\u003ctd\u003ePleiotropic activity across several signaling systems\u003c\/td\u003e\n\u003ctd\u003eActin sequestration and cytoskeletal reorganisation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Research Focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVascular and cytoskeletal research in one preparation\u003c\/td\u003e\n\u003ctd\u003eTissue integrity, vascular and mucosal models\u003c\/td\u003e\n\u003ctd\u003eCell migration and endothelial models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStructural Design\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMixture of two peptides, no single formula or CAS number\u003c\/td\u003e\n\u003ctd\u003eFifteen residues, no unnatural residues or modification\u003c\/td\u003e\n\u003ctd\u003eSeven residues, N terminal acetyl group, free acid C terminus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use blend, neither component approved for human or veterinary use, and the TB-500 component appears on the United States Food and Drug Administration list of bulk drug substances withdrawn from consideration for compounding\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use, and listed by the United States Food and Drug Administration among bulk drug substances withdrawn from consideration for compounding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003cp\u003eWolverine Blend is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eLaboratory Handling and Storage Considerations\u003c\/h2\u003e\n\u003cp\u003eThe co lyophilized blend should be stored sealed at 2 to 8 °C, protected from heat, light and moisture. The powder is hygroscopic, so vials should reach ambient temperature before opening to prevent condensation onto the cake. Because two peptides share one vial, any portion removed carries both components in their blended ratio and the pair cannot be separated by ordinary laboratory handling. Prepared solutions should be aliquoted rather than cycled through freezing and thawing, and every container should carry identity, lot number and preparation date.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory Safety Considerations\u003c\/h3\u003e\n\u003cp\u003eThe practices below apply to routine handling in a research setting.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePersonal protective equipment:\u003c\/strong\u003e Wear nitrile gloves, a laboratory coat and safety glasses whenever a vial is open.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEngineering controls:\u003c\/strong\u003e Weigh and prepare solutions in a certified fume hood to limit powder dispersal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExposure prevention:\u003c\/strong\u003e Avoid skin, eye and mucous membrane contact and wash hands afterwards.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Keep sealed vials at 2 to 8 °C in a dedicated research chemical location.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpill response:\u003c\/strong\u003e Collect spilled powder without raising dust and treat residue as chemical waste.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisposal:\u003c\/strong\u003e Discard unused material and contaminated consumables through the institutional chemical waste stream.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDocumentation:\u003c\/strong\u003e Record lot number, receipt date and each preparation so results stay traceable to a batch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCertificate of Analysis and Quality Assurance\u003c\/h2\u003e\n\u003cp\u003eEvery production lot of Wolverine Blend supplied by Peptsche undergoes analytical evaluation, and a batch specific Certificate of Analysis accompanies each order to support research documentation, quality control and experimental consistency.\u003c\/p\u003e\n\u003cp\u003eEach Certificate of Analysis typically includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity verification\u003c\/strong\u003e using analytical techniques such as mass spectrometry to confirm the molecular characteristics of the material supplied.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity analysis\u003c\/strong\u003e performed by high performance liquid chromatography to quantify purity and identify potential impurities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBatch documentation\u003c\/strong\u003e recording lot number, testing date, analytical methods applied and quality assessment results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTraceability information\u003c\/strong\u003e to support laboratory recordkeeping and reproducibility across research workflows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePeptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification of research material quality. Independent testing provides transparency and confidence in product identity, consistency and sourcing, and batch specific documentation can be retained as part of laboratory records and internal quality procedures.\u003c\/p\u003e\n\u003cp\u003eWolverine Blend is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is Wolverine Blend?\u003c\/h3\u003e\n\u003cp\u003eWolverine Blend is a two component research preparation in which BPC-157 and TB-500 are co lyophilized together in a single sealed vial. Because it is a mixture rather than one defined chemical entity, it has no single molecular formula, molecular weight or CAS number, and each component is specified separately.\u003c\/p\u003e\n\u003ch3\u003eWhat is Wolverine Blend studied for in research?\u003c\/h3\u003e\n\u003cp\u003eThe two components have been studied separately in preclinical work spanning endothelial and vascular cell culture, animal model tissue studies, and cytoskeletal and analytical reference use. No published study characterises this two component blend as such.\u003c\/p\u003e\n\u003ch3\u003eHow does Wolverine Blend work in laboratory research?\u003c\/h3\u003e\n\u003cp\u003eMechanism is described per component. Reports for the BPC-157 component centre on vascular signalling, including nitric oxide observations, while the TB-500 component retains the actin binding motif of thymosin beta 4 and is examined through cytoskeletal endpoints. Whether combining them produces additive, independent or interfering behaviour is an open question the existing evidence base does not answer.\u003c\/p\u003e\n\u003ch3\u003eHow is the quality of Peptsche Wolverine Blend verified?\u003c\/h3\u003e\n\u003cp\u003eEvery production lot of Peptsche Wolverine Blend is evaluated analytically, with identity confirmed using techniques such as mass spectrometry and purity quantified by high performance liquid chromatography. Peptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification, and a batch specific Certificate of Analysis accompanies each order.\u003c\/p\u003e\n\u003ch3\u003eHow should unopened Wolverine Blend be stored?\u003c\/h3\u003e\n\u003cp\u003eUnopened vials should be stored sealed at 2 to 8 °C, protected from heat, light and moisture. Vials should reach ambient temperature before opening, and lot number, storage conditions and preparation date should be recorded in laboratory documentation so results stay traceable to a batch.\u003c\/p\u003e\n\u003ch3\u003eIs Wolverine Blend intended for human use?\u003c\/h3\u003e\n\u003cp\u003eNo. Wolverine Blend is supplied strictly for laboratory research use only. It is not approved for human consumption, veterinary use, diagnosis, treatment or any medical application.\u003c\/p\u003e\n\u003ch3\u003eWhy do researchers choose Peptsche for Wolverine Blend?\u003c\/h3\u003e\n\u003cp\u003eEach component is assayed before blending, so the stated specification of 99% or greater purity by HPLC applies to the batch shipped. Independent third party verification and documentation of both components and the blending ratio support reproducibility across research workflows.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eSeiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, Zenko A, Drmic D, Rucman R, Sikiric P. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1121 to 1125. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23782145\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/23782145\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eHsieh MJ et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src Caveolin 1 endothelial nitric oxide synthase pathway. Scientific Reports. 2020. \u003ca href=\"https:\/\/www.nature.com\/articles\/s41598-020-74022-y\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/www.nature.com\/articles\/s41598-020-74022-y\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eMalinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364 to 368. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10469335\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10469335\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eMalinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal. 1997;11(6):474 to 481. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9194528\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/9194528\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2\u003eRESEARCH USE ONLY\u003c\/h2\u003e\n\u003cp\u003eThese compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.\u003c\/p\u003e","brand":"Peptsche","offers":[{"title":"10mg","offer_id":43752813002815,"sku":"PEP-WOLV-10MG","price":66.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/7394\/0287\/files\/peptsche_Wolverine_Blend_10mg.png?v=1786905447","url":"https:\/\/peptsche.com\/products\/wolverine-blend","provider":"Peptsche","version":"1.0","type":"link"}